

# Special Issue

## Advances and Challenges in Mycobacterium tuberculosis Research and Therapeutics Development

### Message from the Guest Editors

Tuberculosis (TB) is the leading cause of death worldwide from a single infectious agent and is one of the top ten causes of death overall, causing an estimated 10 million infections and 1.4 million deaths in 2019. In recent years, molecular techniques such as GeneXpert and Whole Genome Sequencing have led to improvements in diagnostic efficiency, contact tracing, and resistance testing and contributed to our understanding of key aspects of the organism, such as transmission and virulence. Furthermore, novel therapeutic agents provide more options for treatment of Multi-Drug Resistant Tuberculosis (MDR-TB), and injectable free regimens may in future improve compliance and cure rates. At a time when progress in the fight against TB is being threatened by the global COVID-19 pandemic, it is important to focus on bold technological improvements such as improved vaccines, point-of-care diagnostic testing, treatment for latent TB, and shorter treatment regimens for active TB. For this Special Issue, we invite contributions on all aspects of the development of tuberculosis diagnostics and therapeutics.

### Guest Editors

Dr. Louis Grandjean

Great Ormond Street Hospital London WC1N 3JH, UK; Imperial College London, London SW7 2BU, UK

Dr. Marc Woodman

Guys and St Thomas' NHS Trust, London SE1 9RS, UK

Dr. Shruthi Chandran

Department of Microbiology and Infectious diseases, Royal London Hospital, Barts NHS Health trust, London E1 1FR, UK

### Deadline for manuscript submissions

closed (31 December 2021)



**Microorganisms**

an Open Access Journal  
by MDPI

**Impact Factor 4.2**  
**CiteScore 7.7**  
**Indexed in PubMed**



[mdpi.com/si/66245](https://mdpi.com/si/66245)

*Microorganisms*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[microorganisms@mdpi.com](mailto:microorganisms@mdpi.com)

[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)





## Microorganisms

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.2  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)



## About the Journal

### Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

---

### Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for  
Environmental Research, 04318 Leipzig, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).